Losartan Potassium
Product Images NDC 50090-4252

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-4252). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500904252)

LOSARTAN POTASSIUM 25 MG tablets label from A-S Medication Solutions. The label includes dosage strength, storage instructions to store at 77 degrees F and protect from light, and a package quantity of 90 tablets. It also shows the product number and barcode information.*

FDA Label Image

Fig 2 (Losartanpotassiumfig2)

A line graph showing the percentage of patients with fatal or non-fatal stroke over a study period of 66 months. Two lines compare Losartan Potassium and Atenolol, with Losartan Potassium showing a lower stroke incidence. The graph includes an annotation indicating an adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Fig 4 (Losartanpotassiumfig4)

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium and placebo groups. The graph shows cumulative risk with a 16.1% risk reduction for Losartan Potassium versus placebo (p=0.022). The x-axis represents time in months, and the y-axis represents the percentage of patients with events.*

FDA Label Image

Fig 1 (Losartanpotassiumfigure1)

A line graph comparing the percentage of patients with a primary endpoint over study months for Losartan Potassium and Atenolol. The x-axis shows study duration in months (0 to 66), and the y-axis shows the percentage of patients. Losartan Potassium is represented by a solid line, while Atenolol is shown with a dotted line. The graph notes an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Fig 3 (Losartanpotassiumfigure3)

A clinical data chart presenting hazard ratios with 95% confidence intervals comparing Losartan Potassium and Atenolol for primary composite and stroke (fatal/non-fatal) events. The chart is stratified by patient subgroups including age, gender, race, ischemic heart status, diabetes presence, and cardiovascular disease history, showing event rates and favorability for each treatment.*

FDA Label Image

Losartan Potassium (Losartanpotassiumstrfrm1)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.